Investors May Not Have Seen the Best From Eli Lilly Stock Yet. Here's Why.
When it comes to diabetes treatments and weight-loss supplements, two companies come to mind: Novo Nordisk and Eli Lilly (NYSE: LLY). If you aren't familiar with these companies by name, perhaps you've seen commercials for the medicines Ozempic, Rybelsus, Jardiance, and Mounjaro. All four of these drugs were developed by either Novo Nordisk or Eli Lilly.
While Novo Nordisk currently dominates the weight-loss-supplement market, Eli Lilly might not be far behind. By specifically focusing on Mounjaro, investors may come to see that Eli Lilly has potentially unlocked its next catalyst.
In May 2022, the FDA approved a diabetes injection developed by Eli Lilly called tirzepatide. While that is the formal name for the treatment, the company commercially sells the drug under the name Mounjaro. The drug is specifically used to treat type 2 diabetes and is not meant to be a weight-loss medicine. Well, not yet, at least.
Source Fool.com
